Instruction manual

Contents

	1. Intended Use	1
	2. Clinical Applications and Principle of the Assay	1
	3. Kit Contents	2
	4. Storage and Shelf Life	2
	5. Precautions of Use	3
	6. Sample Collection, Handling and Storage	3
	7. Assay Procedure	4
	8. Quantitative and Qualitative Interpretation	5
	9. Technical Data	6
1	10. Performance Data	6-7
1	11. Literature	7
,	A : Pipetting scheme	8
	B : Test Procedure	9

002 : 2007-08-28 REF 3111 Scl-70

1. Intended Use

AESKULISA ScI-70 is a solid phase enzyme immunoassay with human recombinant 70 kDa fragment of DNA topoisomerase I for the quantitative and qualitative detection of antibodies against ScI-70 (70 kDa scleroderma antigen) in human serum.

The assay is a tool in the differential diagnosis of systemic sclerosis.

2. Clinical Application and Principle of the Assay

Antibodies against ScI-70 are directed against DNA-topoisomerase I which is an enzyme located in the nucleoplasm, nucleolus and nucleolar organizing region. It catalyzes the breaking and rejoining of single stranded DNA thus interconverting different topological forms of DNA, most likely during transcription. The whole antigen has a molecular weight of 110 kDa but is easily degraded by proteases to 100 kDa, 87 kDa and 70 kDa (hence ScI-70).

Anti-Scl-70 belong to the heterogenous group of anti-nuclear antibodies (ANA) which are directed against various proteins of the nucleus. ANAs are associated with various autoimmune diseases. Antibodies against Scl-70 as well as antibodies against the chromosomal centromere protein B (Cenp-B) are highly specific for systemic sclerosis, a multisystemic autoimmune disease with systemic fibrosis of the connective tissue. Antibodies against Scl-70 can be found in 70 % of patients with diffuse cutaneous systemic sclerosis and give a hint for a severe course. Antibodies against Cenp-B are characteristic for a slower progressing variant of systemic sclerosis, the CREST syndrome (occurrence in 70-80 % of CREST patients). The respective antibody has a prognostic value for the disease's progress. It was shown that the presence of both autoantibodies in one patient is very rare.

Principle of the test

Serum samples diluted 1:101 are incubated in the microplates coated with the specific antigen. Patient's antibodies, if present in the specimen, bind to the antigen. The unbound fraction is washed off in the following step. Afterwards anti-human immunoglobulins conjugated to horseradish peroxidase (conjugate) are incubated and react with the antigen-antibody complex of the samples in the microplates. Unbound conjugate is washed off in the following step. Addition of TMB-substrate generates an enzymatic colorimetric (blue) reaction, which is stopped by diluted acid (color changes to yellow). The rate of color formation from the chromogen is a function of the amount of conjugate bound to the antigen-antibody complex and this is proportional to the initial concentration of the respective antibodies in the patient sample.

Page 1 of 9 002 : 2007-08-28 REF 3111 Scl-70

3. Kit Contents

To be reconstituted:

5x Sample Buffer 1 vial, 20 ml - 5x concentrated (capped white: yellow solution)

Containing: Tris, NaCl, BSA, sodium azide < 0.1% (preservative)

50x Wash Buffer 1 vial, 20 ml - 50x concentrated (capped white: green solution)

Containing: Tris, NaCl, Tween, sodium azide < 0.1% (preservative)

Ready to use:

Negative Control 1 vial, 1.5 ml (capped green: colorless solution)

Containing: Human serum (diluted), sodium azide < 0.1% (preservative)

Positive Control 1 vial, 1.5 ml (capped red: yellow solution)

Containing: Human serum (diluted), sodium azide < 0.1% (preservative)

Cut-off Calibrator 1 vial, 1.5 ml (capped blue: yellow solution)

Containing: Human serum (diluted), sodium Azide < 0.1% (preservative)

Calibrators 6 vials, 1.5 ml each 0, 3, 10, 30, 100, 300 U/ml

(color increasing with concentration: yellow solutions)

Containing: Human serum (diluted), sodium azide < 0.1% (preservative)

Conjugate 1 vial,15 ml IgG (capped blue: blue solution)

Containing: Anti-human immunoglobulins conjugated to horseradish peroxidase

TMB Substrate 1 vial, 15 ml (capped black)

Containing: Stabilized TMB/H2O2

Stop Solution 1 vial, 15 ml (capped white: colorless solution)

Containing: 1M Hydrochloric Acid

Microtiterplate 12x8 well strips with breakaway microwells

Coating see paragraph 1

Material required but not provided:

Microtiter plate reader 450 nm reading filter and optional 620 nm reference filter (600-690 nm). Glass ware(cylinder 100-1000ml), test tubes for dilutions. Vortex mixer, precision pipettes (10, 100, 200, 500, 1000 μ l) or adjustable multipipette (100-1000ml). Microplate washing device (300 μ l repeating or multichannel pipette or automated system), adsorbent paper.

Our tests are designed to be used with purified water according to the definition of the United States Pharmacopeia (USP 26 - NF 21) and the European Pharmacopeia (Eur.Ph. 4th ed.).

4. Storage and Shelf Life

Store all reagents and the microplate at 2-8°C/35-46°F, in their original containers. Once prepared, reconstituted solutions are stable for 1 month at 4°C, at least. **Reagents and the microplate shall be used within the expiry date indicated on each component, only. Avoid intense exposure of TMB solution to light. Store microplates in designated foil, including the desiccant, and seal tightly.**

Page 2 of 9 002 : 2007-08-28 REF 3111 Scl-70

5. Precautions of Use

5.1 Health hazard data

This product is for **IN VITRO DIAGNOSTIC USE** only. Thus, only staff trained and specially advised in methods of in vitro diagnostics may perform the kit. Although this product is not considered particularly toxic or dangerous in conditions of normal use, refer to the following for maximum safety:

Recommendations and precautions

This kit contains potentially hazardous components. Though kit reagents are not classified being irritant to eyes and skin we recommend to avoid contact with eyes and skin and wear disposable gloves.

WARNING! Calibrators, Controls and Buffers contain sodium azide (NaN₃) as a preservative. NaN₃ may be toxic if ingested or adsorbed by skin or eyes. NaN₃ may react with lead and copper plumbing to form highly explosive metal azides. On disposal, flush with a large volume of water to prevent azide build-up. Please refer to decontamination procedures as outlined by CDC or other local/national guidelines.

Do not smoke, eat or drink when manipulating the kit.

Do not pipette by mouth.

All human source material used for some reagents of this kit (controls, standards e.g.) has been tested by approved methods and found negative for HbsAg, Hepatitis C and HIV 1. However, no test can guarantee the absence of viral agents in such material completely. Thus handle kit controls, standards and patient samples as if capable of transmitting infectious diseases and according to national requirements.

5.2 General directions for use

Do not mix or substitute reagents or microplates from different lot numbers. This may lead to variations in the results.

Allow all components to reach room temperature (20-32°C/68-89.6°F) before use, mix well and follow the recommended incubation scheme for an optimum performance of the test.

Incubation: We recommend test performance at 30°C/86°F for automated systems.

Never expose components to higher temperature than 37°C/98.6 °F.

Always pipette substrate solution with brand new tips only. Protect this reagent from light. Never pipette conjugate with tips used with other reagents prior.

A definite clinical diagnosis should not be based on the results of the performed test only, but should be made by the physician after all clinical and laboratory findings have been evaluated. The diagnosis is to be verified using different diagnostic methods.

6. Sample Collection, Handling and Storage

Use preferentially freshly collected serum samples. Blood withdrawal must follow national requirements.

Do not use icteric, lipemic, hemolysed or bacterially contaminated samples. Sera with particles should be cleared by low speed centrifugation (<1000 x g). Blood samples should be collected in clean, dry and empty tubes. After separation, the serum samples should be used immediately, respectively stored tightly closed at $2-8^{\circ}\text{C}/35-46^{\circ}\text{F}$ up to three days, or frozen at $-20^{\circ}\text{C}/-4^{\circ}\text{F}$ for longer periods.

Page 3 of 9 002 : 2007-08-28 REF 3111 Scl-70

7. Assay Procedure

7.1 Preparations prior to pipetting

Dilute concentrated reagents:

Dilute the concentrated sample buffer 1:5 with distilled water (e.g. 20 ml plus 80 ml). Dilute the concentrated wash buffer 1:50 with distilled water (e.g. 20 ml plus 980 ml).

Samples:

Dilute serum samples 1:101 with sample buffer (1x) e.g. 1000 μl sample buffer (1x) + 10 μl serum. Mix well!

Washing:

Prepare 20 ml of diluted wash buffer (1x) per 8 wells or 200 ml for 96 wells e.g. 4 ml concentrate plus 196 ml distilled water.

Automated washing:

Consider excess volumes required for setting up the instrument and dead volume of robot pipette.

Manual washing:

Discard liquid from wells by inverting the plate. Knock the microwell frame with wells downside vigorously on clean adsorbent paper. Pipette 300 µl of diluted wash buffer into each well, wait for 20 seconds. Repeat the whole procedure twice again.

Microplates:

Calculate the number of wells required for the test. Remove unused wells from the frame, replace and store in the provided plastic bag, together with desiccant, seal tightly (2-8°C/35-46°F).

7.2 Work flow

For pipetting scheme see Annex A, for the test procedure see Annex B We recommend pipetting samples and calibrators in duplicate.

Cut-off calibrator should be used for qualitative testing only.

- Pipette 100 μl of each patient's diluted serum into the designated microwells.
- Pipette 100 µl calibrators OR cut-off calibrator and negative and positive controls into the designated wells.
- Incubate for 30 minutes at 20-32°C/68-89.6°F.
- Wash 3x with 300 μl washing buffer (diluted 1:50).
- Pipette 100 µl conjugate into each well.
- Incubate for 30 minutes at 20-32°C/68-89.6°F.
- Wash 3x with 300 µl washing buffer (diluted 1:50).
- Pipette 100 µl TMB substrate into each well.
- Incubate for 30 minutes at 20-32°C/68-89.6°F, protected from intense light.
- Pipette 100 µl stop solution into each well, using the same order as pipetting the substrate.
- Incubate 5 minutes minimum.
- Agitate plate carefully for 5 sec.
- Read absorbance at 450 nm (optionally 450/620 nm) within 30 minutes.

Page 4 of 9 002 : 2007-08-28 REF 3111 Scl-70

8. Quantitative and Qualitative Interpretation

For quantitative interpretation establish the standard curve by plotting the optical density (OD) of each calibrator (y-axis) with respect to the corresponding concentration values in U/ml (x-axis). For best results we recommend log/lin coordinates and 4-Parameter Fit. From the OD of each sample, read the corresponding antibody concentrations expressed in U/ml.

Normal Range	Equivocal Range	Positive Results		
< 12 U/ml	12 - 18 U/ml	>18 U/ml		

Example of a standard curve

We recommend pipetting calibrators in parallel for each run.

Calibrators IgG	OD 450/620 nm	CV % (Variation)
0 U/ml	0.033	2.9
3 U/ml	0.137	3.0
10 U/ml	0.311	1.9
30 U/ml	0.629	2.6
100 U/ml	1.285	2.2
300 U/ml	2.277	0.2

Example of calculation

Patient	Replicate (OD)	Mean (OD)	Result (U/ml)	
P 01	0.978/1.006	0.992	62.1	
P 02	0.633/0.653	0.643	31.8	

For lot specific data, see enclosed quality control leaflet. Medical laboratories might perform an inhouse Quality Control by using own controls and/or internal pooled sera, as foreseen by EU regulations.

Do not use this example for interpreting patients results!

Each laboratory should establish its own normal range based upon its own techniques, controls, equipment and patient population according to their own established procedures.

For qualitative interpretation read the optical density of the cut-off calibrator and the patient samples. Compare patient'sOD with the OD of the cut-off calibrator. For qualitative interpretation we recommend to consider sera within a range of 20% around the cut-off value as equivocal. All samples with higher ODs are considered positive, samples with lower ODs are considered negative.

Negative: OD patient < 0.8 x OD cut-off

Equivocal: $0.8 \times OD_{cut-off} \le OD_{patient} \le 1.2 \times OD_{cut-off}$

Positive OD patient > 1.2 x OD cut-off

Page 5 of 9 002 : 2007-08-28 REF 3111 Scl-70

9. Technical Data

Sample material: serum

Sample volume: 10 μl of sample diluted 1:101 with 1x sample buffer

Total incubation time: 90 minutes at 20-32°C/68-89.6°F

Calibration range: 0-300 U/ml

Analytical sensitivity: 1.0 U/ml

Storage: at 2-8°C/35-46°F use original vials, only

Number of determinations: 96 tests

10. Performance Data

10.1 Analytical sensitivity


Testing sample buffer 30 times on *AESKULISA ScI-70 (REF7111)* gave an analytical sensivity of 1.0 U/ml.

10.2 Specificity and Sensitivity

The microplates are coated with recombinant *human 70 kDa fragment of DNA topoisomerase I.* No crossreactivities to other autoantigens have been found. The diagnostic specificity of Scl-70 antibodies for systemic sclerosis is almost 100%. The diagnostic sensitivity of Scl-70 antibodies for systemic sclerosis ranges between 20-48%. The data has been aquired with the *AESKULISA Scl-70 (REF7111)*.

Correlation:

The comparability of performance data was assessed with 50 sera tested on both, *AESKULISA* 7111 and *AESKULISA* 3111. A linear regression analysis of the two products showed that the two products are equivalent. Included in these sera are 30 sera close to cut-off.



Page 6 of 9 002 : 2007-08-28 REF 3111 Scl-70

10.3 Linearity

Chosen sera have been tested with this kit and found to dilute linearly. However, due to the heterogeneous nature of human autoantibodies there might be samples that do not follow this rule.

		measured	expected	
Sample	Dilution	concentration	concentration	Recovery
No.	Factor	(U/ml)	(U/ml)	(%)
1	1 / 100	87.0	86.0	101.2
	1 / 200	41.8	43.0	97.2
	1 / 400	20.3	21.5	94.4
	1 / 800	9.8	10.8	90.7
2	1 / 100	51.9	52.0	99.8
	1 / 200	24.3	26.0	93.5
	1 / 400	12.8	13.0	98.5
	1 / 800	7.0	7.5	93.3

10.4 Precision

To determine the precision of the assay, the variability (intra and inter-assay) was assessed by examining its reproducibility on three serum samples selected to represent a range over the standard curve.

Intra-Assay									
Sample Mean CV									
No.	(U/ml)	(%)							
1	66.5	7.7							
2	37.7	4.3							
3	19.4	1.9							

Inter-Assay								
Sample Mean CV								
No.	(U/ml)	(%)						
1	57.5	4.4						
2	52.2	4.2						
3	17.7	1.3						

10.5 Calibration

The AESKULISA ScI-70 is calibrated against reference sera from the CDC Atlanta (Centers for Disease Control and Prevention). The results are expressed in U/ml.

11. Literature

1. Gilmour DS, Elgin SCR (1987).

Localization of specific topoisomerase I interactions within the transcribed region of active heat shock genes by using the inhibitor camptothecin.

Mol Cell Biol 7: 141-148.

2. Ruffatti A, Calligaro A, Ferri C, et al. (1985).

Association of anticentromere and anti-Scl-70 antibodies in scleroderma. Report of two cases. J Clin Lab immunol 16: 227-229.

3. Douvas AS, Achten M, Tan EM. (1979).

Identification of a nuclear protein (ScI-70) as a unique target of human antinuclear antibodies in scleroderma.

J Biol Chem 254: 10514-10522.

4. Tan EM, (1989).

Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology.

Adv Immunol 44: 93-151.

ANNEX A: Pipetting scheme

We suggest pipetting calibrators, controls and samples as follows:

For quantitative interpretation use calibrators to establish a standard curve.

For **qualitative interpretation** use cut-off calibrator.

	for quantitative interpretation use calibrators to establish a standard curve							for qualitative interpretation use cut- off calibrator				
	1	2	3	4	5	6	7	8	9	10	11	12
Α	CalA	CalE	P1				NC	P2				
В	CalA	CalE	P1				NC	P2				
С	CalB	CalF	P2				CC	P3				
D	CalB	CalF	P2				CC	P3				
Ε	CalC	PC	P3				PC					
F	CalC	PC	P3				PC					
G	CalD	NC					P1					
Н	CalD	NC					P1					


CalA: calibrator A, CalB: calibrator B, CalC: calibrator C, CalD: calibrator D, CalE: calibrator E,


CalF: calibrator F PC: positive control NC: negative control CC: Cut-off calibrator


P1: patient 1 P2: patient 2 P3: patient 3

Page 8 of 9 002 : 2007-08-28 REF 3111 Scl-70

Annex B: Test Procedure







			11 12								
Date/ Datum:	Signature/Unterschrift:		10								
Date/	11/	gnature/ Un	6								
	S	Z.	8								
min_	mim_	mim	7								
<u></u>	.5	3.	9								
Inkub. :	<i>T</i>)		5								
Incubation / Inkub. :	J.		4								
<u> </u>	9-F		3								
	tur:	mr.	7								
	emperature/Temperatur:_		-1								
ssay/Test:	emperatur	Vame:		A	В	Э	D	E	F	Ð	Н

AESKU.DIAGNOSTICS GmbH 55234 Wendelsheim - Mikroforum Ring 2, Germany Phone: +49-6734-96270, Fax: +49-6734-962727

	◆ Diagnosi in vitro	 For in vitro diagnostic use
ן מעו	Pour diagnostic in vitro	◆ Para uso diagnóstico in vitro
ועט	♦ In Vitro Diagnostikum	♦ In Vitro Διαγνωστικό μέσο
	◆ Para uso Diagnóstico in vitro	
	◆ Numero d'ordine	◆ Cataloge number
REF	♦ Référence Catalogue	♦ Numéro de catálogo
1\L1	Bestellnummer	◆ Αριθμός παραγγελίας
	♦ Número de catálogo	
	◆ Descrizione lotto	♦ Lot
LOT	♦ Lot	♦ Lote
LOT	◆ Chargen Bezeichnung	★ Χαρακτηρισμός παρτίδας
	♦ Lote	
	◆ Conformità europea	◆ EC Declaration of Conformity
C€	◆ Déclaration CE de Conformité	◆ Declaración CE de Conformidad
	◆ Europäische Konformität	◆ Ευρωπαϊκή συμφωνία
	◆ Déclaração CE de Conformidade	
	♦ 96 determinazioni	♦ 96 tests
\96/	♦ 96 tests	♦ 96 pruebas
	◆ 96 Bestimmungen	◆ 96 προσδιορισμοί
	♦ 96 Testes	
	♦ Rispettare le istruzioni per l'uso	 See instructions for use
	♦ Voir les instructions d'utilisation	 Ver las instrucciones de uso
$\downarrow 1$	 Gebrauchsanweisung beachten 	 Λάβετε υπόψη τις οδηγίες χρήσης
~	♦ Ver as instrucões de uso	
	◆ Da utilizzarsi entro	♦ Use by
\ <u>\</u>	◆ Utilise avant le	♦ Utilizar antes de
	♦ Verwendbar bis	Χρήση μέχρι
	◆ Utilizar antes de	
∩ ~+8°C	♦ Conservare a 2-8°C	♦ Store at 2-8°C (35-46°F)
1 −+8°C	♦ Conserver à 2-8°C	♦ Conservar a 2-8°C
+2°C-	♦ Lagerung bei 2-8°C	♦ Φυλάσσεται στους 2-8°C
	♦ Conservar entre 2-8°C	<u> </u>
	♦ Prodotto da	◆ Manufactured by
A A	♦ Fabriqué par	♦ Fabricado por
	♦ Hergestellt von	 Κατασκευάζεται από
	◆ Fabricado por	y
	◆ Calibratore cut-off	◆ Cut off Calibrator
00 041	♦ Etalon Seuil	Calibrador de cut-off
CU-CAL	Grenzwert Kalibrator	 Οριακός ορός Αντιδραστήριο βαθμονόμησης
	Calibrador de cut-off	- 1 - 1 - 2 - 1 - 2 - 1 - 1 - 1 - 1 - 1
	Controllo positivo	◆ Positive Control
CONI	◆ Controllo positivo ◆ Contrôle Positif	◆ Control Positivo
CON +	Positiv Kontrolle	 Φετικός ορός ελέγχου
	◆ Controlo positivo	* Opinios obos evestion
	Controllo positivo Controllo negativo	♦ Negative Control
0011	Contrôle Négatif Contrôle Négatif	◆ Control Negativo
CON -	Negativ Kontrolle	◆ Αρνητικός ορός ελέγχου
22.1	Controlo negativo	· Apriliance obed everyou
	◆ Calibratore	◆ Calibrator
	♦ Etalon	Calibrator Calibrador
l CAL II	♦ Kalibrator	 ◆ Αντιδραστήριο βαθμονόμησης
J. 1.2	♦ Calibrator	τ τιποραστηρίο ρασμοτομήσης
	♦ Recupero	♦ Recovery
	◆ Corrélation	◆ Recovery ◆ Recuperado
RC	Wiederfindung	Ανάκτηση
	◆ Recuperacão	* /www.ijorj
	·	▲ Conjugato
	♦ Conjugé	◆ Conjugate
CONJ	◆ Conjugé◆ Konjugat	◆ Conjugado◆ Σύζευγμα
	◆ Conjugat ◆ Conjugado	. ==>==1
		▲ Coated microtitor plots
	 Micropiastra rivestita Microplaque sensibilisée 	 ◆ Coated microtiter plate ◆ Microplaca sensibilizada
MP	Micropiaque sensibilisee Beschichtete Mikrotiterplatte	 νιιστοριασα sensibilizada € Επικαλυμμένη μικροπλάκα
	Microplaca revestida	• Επικαλομμένη μικροπλακά
	·	▲ Coated pipulate
-	 ◆ Piastra ad aghi rivestita ◆ Pinplate sensibilisée 	◆ Coated pinplate ◆ Pinplate sensibilizada
PINP	 ◆ Pinplate sensibilisee ◆ Beschichtete Pinplatte 	 Pinplate sensibilizada Επικαλυμμένη πλάκα Pin
1 1141	Beschichtete Pinplatte Pinplate revestida	♦ Επικαλυμμένη πλάκα Pin
		▲ Wooh huffer
	◆ Tampon de Lavaggio	♦ Wash buffer
WASHB 50x	◆ Tampon de Lavage	♦ Solución de lavado
* # (OTTD OOK	♦ Waschpuffer	◆ Ρυθμιστικό διάλυμα πλύσης
	♦ Solucão de lavagem	
	Tampone substrato	Substrate buffer
SUB	♦ Substrat	♦ Tampón sustrato
308	Substratpuffer	 Ρυθμιστικό διάλυμα υποστρώματος
	◆ Substrato	
	♦ Reagente bloccante	◆ Stop solution
CTOD	♦ Solution d'Arrêt	 ♦ Solución de parada
[3107]	◆ Stopreagenz	 Αντιδραστήριο διακοπής αντίδρασης
	♦ Solução de paragem	
	◆ Tampone campione	♦ Sample buffer
00.5	◆ Tampon Echantillons	◆ Tampón Muestras
SB 5x	♦ Probenpuffer	 Ρυθμιστικό διάλυμα δειγμάτων
	Diluente de amostra	, , , , , , , , , , , , , , , , , , ,